Drug intelligence / Profile preview

DA-5215

Development stage: Preclinical
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Oral

Overview

DA-5215 is an orally administered drug candidate developed by Dong-A ST. It is being investigated in the field of immunology, specifically for the treatment of psoriasis. As of the latest available information, it has reached the IND/CTA (Investigational New Drug/Application for Clinical Trial Authorization) filing stage in South Korea. The precise mechanism of action and molecular target have not been publicly disclosed.

Brand names: Oteze
Other names: apremilastDA-5215-RDA5215-RDA 5215-R

Targets

PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on DA-5215.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-5215.

Explore the full profile